AHA to AztraZeneca Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs

AHA to AztraZeneca Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Related Resources

Webinar Recordings
Member
Your browser does not support the video tag.
Guides/Reports
Public
In 2017 alone, 340B Tax-exempt Hospitals Provided More Than $64 Billion in Total Benefits to Their Communities   Improving the health of their…
Action Alert
Member
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana…
Letter/Comment
Public
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our…
Letter/Comment
Public
On behalf of the nation’s 340B hospitals, AHA, others urge the Department of Health and Human Services (HHS) to protect vulnerable communities from actions…
Letter/Comment
Public
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to…